OBJECTIVES: Health Transformation Program was started at year 2002 by Ministry of Health(MoH) in Turkey. Today, Turkey has a well established health system mostly dominated by government on healthcare provider and payer. The program allows the patient access to all drugs. There was an increasing trend for the pharmaceutical consumption in years depending on the taken policies as other healthcare services. The aim of this study is to review an analysis for the new drug release prices for Turkey in the recent years.  METHODS: The data was obtained from the last price list of each calender year published by MoH for the years between 2009-2014. The year 2014 year data limited with the first quarter(Q1). The data classified in three groups which were; over 100 TL, over 1000 TL and over 10000 TL. All the result were based on ex-factory prices. A descriptive analysis was conducted on the price lists with the number of the products, maximum and average ex-factory prices.  RESULTS: The numbers of new released products over 100 TL were; 1,7,58,36 and 52 in the years 2009,2010,2011,2012 and 2013, respectively. The numbers of new released products over 1000 TL were; 0,1,10,11 and 13 in the years 2009,2010,2011,2012 and 2013, respectively. The highest ex-factory prices were 739 TL,1117 TL,4066,72 TL,5781,05 TL,22791,55 TLand 36577,33  in the years 2009,2010,2011,2012 and 2013, respectively. The average ex-factory prices were 178,98 TL, 329,28 TL, 214,36 TL, 312,93, 497,44 TL and 612,85 TL in the years 2009,2010,2011,2012,2013 and 2014Q1 respectively.  CONCLUSIONS: It was shown that the number of high prices drugs, the highest price and the average price of the new drugs were increased year by year. Increased patient access may encoruage pharmaceutical companies to enter the Turkish market with their innovative drugs which have high price tag compared to regular drugs.